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A B S T R A C T
We present a 27-year-old lady with HIV-1 infection who died due to rapidly worsening respiratory failure one
day after commencing amphotericin B deoxycholate therapy for cryptococcal meningitis. Chest x-ray
appearances were consistent with pneumocystis pneumonia but post mortem examination showed evidence of
severe necrotizing cryptococcal pneumonia. Cryptococcal pneumonia is an underrecognized condition and
should be considered in the diﬀerential of patients with HIV-1 infection and low CD4 count who develop
respiratory symptoms.
1. Introduction
Cryptococcosis is an invasive mycosis, caused by the environmental
yeast Cryptococcus neoformans. Infection occurs via the inhalational
route and although exposure is common, invasive disease is usually
restricted to individuals with impaired cell-mediated immunity [1].
Due to the ongoing HIV epidemic it remains a signiﬁcant cause of
morbidity and mortality in sub-Saharan Africa [2,3]. The most com-
monly recognized and severe presentation is cryptococcal meningitis
but other organ systems can also be aﬀected including the lungs, skin,
and the eye [4]. Here we present a fatal case of HIV-associated
cryptococcal meningitis complicated by rapidly worsening respiratory
failure after commencing amphotericin B deoxycholate anti-fungal
therapy. Post mortem examination of the lungs revealed the underlying
cause to be necrotizing cryptococcal pneumonia. The patient had been
enrolled into a cohort study in Cape Town, South Africa and had
provided written informed consent. The University of Cape Town
Human Research Ethics Committee granted ethical approval for the
study (408/2010 and 371/2013).
2. Case
A 27-year old woman with established HIV-1 infection presented to
hospital with a one-month history of headache, neck stiﬀness, vomiting,
blurred vision and cough (Day 0). She had been started on anti-
retroviral therapy (stavudine, lamivudine and efavirenz) ﬁve years
previously but three months prior to admission (Day −90) had been
changed to zidovudine, lamivudine, and lopinavir/ritonavir by her
local clinic after her CD4 count was measured at 24 cells/μL. When she
arrived at hospital she was apyrexial, her heart rate was 118 beats per
minute, her blood pressure was 104/64 mmHg, respiratory rate was 20
breaths per minute and oxygen saturations 95% on room air. There was
no impairment of consciousness, she had mild meningism but no focal
neurological abnormalities and normal fundoscopy; her chest was clear
to auscultation. A lumbar puncture was performed: opening pressure
was not raised (11 cmH20), cerebrospinal ﬂuid (CSF) leukocyte count
was normal (3 cells/μL, all lymphocytes), CSF protein was 0.56 g/L and
glucose 2.7 mmol/L (serum glucose 5.1 mmol/L). India ink examina-
tion revealed the presence of encapsulated yeasts and CSF cryptococcal
antigen test was positive. Other blood tests revealed a macrocytic
anaemia (Hb 8.1 g/L, MCV 108 fL), reduced albumin (19 g/L), elevated
C-reactive protein (95.4 mg/L), but normal renal and hepatic function.
She was diagnosed with cryptococcal meningitis (Day 0) and started
on intravenous amphotericin B deoxycholate 1 mg/kg daily with oral
ﬂuconazole 800 mg daily as per local guidance [5]. Anti-retroviral
medications were continued. The following day (Day+1) she deterio-
rated markedly with worsening breathlessness. On examination her
heart rate was 150 beats per minute, respiratory rate was 35 breaths per
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minute and oxygen saturation was 80% breathing room air. Her chest
was clear to auscultation but a chest x-ray showed bilateral diﬀuse
ground glass changes more extensive on the right side [Fig. 1].
A presumptive diagnosis of Pneumocystis jirovecii pneumonia was
made and she was treated empirically with high dose co-trimoxazole
(1920 mg three times daily) and prednisone 40 mg twice daily along
with high ﬂow oxygen (Day+1). Although her condition initially
stabilized she deteriorated the following day with worsening respira-
tory failure and died (Day+2). Her family provided written informed
consent for post mortem examination. Subsequent results revealed a
CD4 count of 45 cells/μL and HIV viral load 296 copies/mL (Day+3);
Cryptococcus neoformans was isolated from both cerebrospinal ﬂuid and
blood (Day+3).
At post mortem (Day+7), both lungs showed elevated ﬁrm, grey-
red, poorly demarcated areas of consolidation. There was no cavity
formation or caseous necrosis and the cut surface showed accumula-
tions of thick mucoid secretions [Fig. 2].
Histological examination showed diﬀuse expansion of almost all
airspaces by abundant mucoid colonies of encapsulated yeasts, high-
lighted by Periodic acid–Schiﬀ (PAS), Southgate's mucicarmine [Fig. 3]
and Grocott's Gomori's Methenamine Silver stains [Fig. 4]. The alveolar
septae appeared slightly thickened by a mild inﬁltrate of lymphocytes
and macrophages [Fig. 5]. No histological evidence for pneumocystis
pneumonia was found; the cause of death was recorded as cryptococcal
pneumonia.
3. Discussion
Although meningoencephalitis is the most widely recognized man-
ifestation of cryptococcosis, pulmonary involvement is well described
[6]. The clinical presentation of cryptococcosis is highly dependent on
the host immune response. In an immune competent host the infection
may be asymptomatic and localized solely to the lung while in the
context of profound immune suppression pulmonary involvement can
be extensive and part of a wider, disseminated, infection. This is
Fig. 1. Chest X-ray on Day+1, diﬀuse interstitial shadowing noted throughout both lung
ﬁelds, greater on the right.
Fig. 2. Cut surface of the fresh lung demonstrating poorly demarcated areas of
consolidation with thick mucoid secretions. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Lung tissue (mucicarmine stain, x40), numerous encapsulated yeasts are seen
(marked by black arrow).
Fig. 4. Lung tissue (Grocott's stain, x40), numerous cryptococci are seen throughout the
section, stained dark purple (marked with black arrow).
Fig. 5. Lung tissue with CD68 immunoperoxidase stain highlighting alveolar macro-
phages with dark brown intracytoplasmic staining (see arrows; x40).
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demonstrated by post-mortem studies of persons who had died from
HIV-associated cryptococcal meningitis, which have shown histopatho-
logical evidence of pulmonary cryptococcosis in 38–52% of cases [7,8].
Typical symptoms of pulmonary cryptococcosis include cough, fever,
chest pain, weight loss, dyspnoea, and haemoptysis while chest x-ray
changes include pulmonary nodules, masses, lymphadenopathy, lobar
consolidation, reticulonodular inﬁltrates and pleural eﬀusions [6].
Given the non-speciﬁc clinical features, it is highly likely that
pulmonary cryptococcosis is under-recognized by clinicians. Among
patients with HIV-1 infection it may be misdiagnosed as tuberculosis,
bacterial pneumonia or Pneumocystis jirovecii pneumonia [9]. This was
emphasized by a post mortem study of the lungs of South African
miners in which histological evidence of pulmonary cryptococcosis was
noted in 589 of 8421 miners (7%). While a respiratory cause of death
was recorded for 263 of these miners (44.7%), only 7 (2.7%) were
diagnosed with cryptococcal pneumonia prior to their death. Instead
miners were erroneously diagnosed as having pulmonary tuberculosis
(66.2%) or bacterial pneumonia (24%) [8].
Respiratory failure has been previously described in pulmonary
cryptococcosis with retrospective studies from the USA prior to the
development of anti-retroviral therapy reporting it in up to 9% of
patients [9]. In our recent prospective cohort study in Cape Town, acute
respiratory failure developed in 3% (2 of 60) individuals treated for
HIV-associated cryptococcal meningitis [10]. In both cases respiratory
disease was not evidence clinically at presentation to hospital but
developed rapidly after commencing treatment with amphotericin B
deoxycholate and ﬂuconazole. This time course suggests that the
respiratory deterioration may have been provoked by starting anti-
fungal therapy. Possible mechanisms for this include the release of
antigens following fungal killing or amphotericin B-mediated release of
pro-inﬂammatory cytokines [11]. Given the switch in anti-retroviral
therapy 3 months prior to presentation, it is also possible that
unmasking cryptococcal immune reconstitution inﬂammatory syn-
drome may have played an additional role [12].
Given these ﬁndings, there should be a greater awareness of the
non-neurological manifestations of cryptococcosis, especially in pa-
tients with disseminated disease in the context of immune deﬁciency.
Further work is also required to determine the incidence of acute
respiratory deterioration following initiation of amphotericin B therapy
and the pathophysiology behind this.
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